Article Text
Therapeutics
Systematic review
Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications
Statistics from Altmetric.com
Context
Superficial thrombophlebitis (ST), an inflammatory-thrombotic disorder in a superficial vein, is relatively common and estimated to occur in 1 per 1000 persons.1 The classic symptoms include pain, oedema, erythema and occasionally a palpable cord in the area of the thrombosed vein. Risk factors for ST include surgery, pregnancy and puerperium, female hormones, malignancy, infection, varicose veins, autoimmune disorders and thrombophilia.2 ST is a risk factor for deep venous thrombosis (DVT); 12–44% of patients with ST develop a DVT.3 The treatment of ST is highly variable ranging from no treatment to treatments with non-steroidal anti-inflammatory drugs, …